Whether your personal interests are in supporting innovation, bringing lifesaving biomedical products to patients, training the next generation of biomedical leaders or fueling our economy, the Center for Biotechnology provides a vehicle to accomplish great things. Things that matter. Things that change, and save, lives.
Your involvement is an essential part of our future. Please consider a gift to the Center for Biotechnology which will help fuel innovation by ensuring that lifesaving technologies make it out of research labs and into the hands of patients.
Give to the Center for Biotechnology online through the Stony Brook Foundation. Contributions can be made to our Fund for Excellence. More information about donating through the Stony Brook Foundation can be found here.
The next HHS SBIR/STTR application deadline is less than two months away on Tuesday, September 6, 2016 at 5 pm local time. (Note – the standard deadline falls on September 5, a federal holiday, so the revised deadline is September 6).
Make sure you are registered! The 5-step registration process may take 6 – 8 weeks, so it is important to start now. All registrations must be completed prior to the application being submitted, and the System for Awards Management (SAM) registration must be updated annually. Learn more about the five required registrations, here.
Don’t be shy – speak to an HHS SBIR/STTR Program Manager! It is critical for success that applicants speak to a program manager before submitting! You should send the program manager a non-confidential abstract or executive summary of your research topic, including a description of your technology, which may include your specific aims. After you connect via email, you and the program manager may decide to set up a call to discuss your application in more detail. For questions about who to contact, please email email@example.com.
ASSIST vs. Downloadable Forms – You may submit your application using ASSIST or the Downloadable Forms method, starting on March 5, 2016. Please select the “Apply Online Using ASSIST” button, or the “Apply Using Downloadable Forms” button within the SBIR/STTR solicitation. View the ASSIST webinar materials here.
Be sure to use the Annotated SF424 SBIR/STTR Form Set in conjunction with the SF424 R&R SBIR/STTR Application Guide (FORMS-D) to guide you step-by-step through the application process. Applicants also find the Top 5 Most Common eRA Commons Errors and the SBIR Sample Application from NIAID helpful. All resources can be found on our Resources page.
Remember – The standard due dates occur on September 5, January 5, and April 5. The standard due dates apply to all SBIR/STTR solicitations that follow the Standard Due Dates, including the SBIR/STTR Omnibus solicitations and the Commercialization Readiness Pilot Program solicitations. You can find all solicitations here.
SBIR/STTR Grant Proposal Writing Clinic
July 13th and 14th, 8:30am – 4:30am
Small Business Development Center
Stony Brook University R&D Park
The Small Business Development Center (SBDC) at Stony Brook University is holding a free SBIR/STTR Phase I Proposal Writing Clinic July 13, 2016, followed by one-on-one counseling for in process SBIR/STTR proposals on July 14, 2016. Presented and instructed by Sharon Ballard of Enable Ventures, Inc. This clinic will hone your skills and help you to prepare proposals for Phase I or Phase II SBIR/STTR grants.
In order to participate in the clinic you must become a SBDC client. The SBDC will examine your proposed idea to make sure it will qualify for this program. Space in the July clinic is limited. The deadline for submission is June 17, 2016.
Please answer the questions and submit those answers via soft copy to the following email address: firstname.lastname@example.org. The submissions will be reviewed by committee. Those selected to participate will be notified after June 17th.
TheraSource LLC, a Feinstein Institute for Medical Research spin-out, has received a $3 million three-year Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH). The grant will support the development of human ghrelin as an innovative treatment to alleviate health damage caused by unintentional radiation exposure.
TheraSource has been a client of the Center for Biotechnology and the organization is proud to have played an integral role in the helping the company advance their business and technology strategy. As noted by Diane Fabel, Director of Operations for the Center for Biotechnology, “The Phase II award for TheraSource is a significant landmark for the company and an important milestone for the region.”
Ping Wang, MD, founder of TheraSource and Chief of Scientific Officer (CSO) of the Feinstein Institute has stated “Human ghrelin has been investigated in clinical trials of other indications. With our new findings, we will soon be able to file an Investigational New Drug application to US Food and Drug Administration,” said Dr. Wang. “TheraSource has received investments to fund its various projects and is seeking strategic partnerships towards the goal of clinical development and commercialization.”
For more details, read the company’s press release here.